Table 1.
PAI | Gene | Prevalence (%)a |
|||||
---|---|---|---|---|---|---|---|
Association with SPTs related to outbreak |
Association with SPTs related to severe disease |
Association with LEE |
|||||
In SPTs A and B (n = 34) | In SPTs C, D and E (n = 64) | In STEC SPTs A, B, and C (n = 56) | In STEC in SPTs D and E (n = 42) | In eae-positive STEC (n = 54) | In eae-negative STEC (n = 44) | ||
OI-122 | 55.82* | 17.18* | 46.43† | 9.52† | 55.56‡ | 0‡ | |
pagC | 70.59 | 46.88 | 69.64 † | 35.71† | 64.81‡ | 38.64‡ | |
sen | 100.00* | 31.25* | 76.79 † | 26.45† | 100.00‡ | 2.27‡ | |
efa-1 | 82.35* | 31.25* | 66.07† | 30.95† | 88.89‡ | 6.82‡ | |
efa-2 | 82.35* | 31.25* | 66.07† | 26.45† | 88.89‡ | 2.27‡ | |
nleB | 100.00* | 31.25* | 76.79† | 26.45† | 100.00‡ | 2.27‡ | |
OI-43/48 | 32.35 | 12.50 | 26.79 | 14.28 | 37.03‡ | 2.27‡ | |
terC | 76.47* | 35.94* | 62.50† | 33.33† | 81.48‡ | 11.36‡ | |
ureC | 76.47* | 31.25* | 62.50† | 26.45† | 81.48‡ | 4.54‡ | |
iha | 64.70 | 70.31 | 64.29 | 73.80 | 57.41‡ | 84.09‡ | |
aidA-1 | 38.23 | 32.81 | 39.28 | 28.57 | 65.91‡ | 18.18‡ | |
OI-57 | 82.35* | 21.86* | 60.71† | 19.05† | 75.93‡ | 2.27‡ | |
nleG2-3 | 97.06* | 31.25* | 73.21† | 28.57† | 94.44‡ | 6.82‡ | |
nleG5-2 | 82.35* | 21.88* | 60.71† | 19.04† | 85.19‡ | 2.27‡ | |
nleG6-2 | 97.18* | 28.13* | 66.07† | 28.57† | 75.93‡ | 4.56‡ | |
HPI | 17.65 | 25.00 | 17.86 | 28.57 | 25.92 | 18.18 | |
fyuA | 17.65 | 23.44 | 16.07 | 28.57 | 25.92 | 18.18 | |
irp2 | 17.65 | 23.44 | 16.07 | 28.57 | 25.92 | 18.18 |
*, Statistically significant difference between SPTs A and B compared to SPTs C, D, and E; †, statistically significant difference between SPTs A, B, and C compared to SPTs D and E; ‡, statistically significant difference between eae-positive and eae-negative STEC. A P value of <0.01 was considered statistically significant.